Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Genmab A/S has received a consensus recommendation of "Moderate Buy" from eleven analysts, with an average one-year target price of $37.60.
• Institutional investors have significantly increased their positions in Genmab, including Orbis Allan Gray Ltd which raised its position by 102.8% in Q1.
• Genmab reported $0.54 EPS in its last earnings release, exceeding analysts' expectations, and had revenue of $925 million for the quarter.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $37.60.

Several brokerages recently weighed in on GMAB. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday, July 28th. HC Wainwright lifted their price target on Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a research report on Friday, August 15th. Truist Financial lifted their price target on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Finally, Zacks Research cut Genmab A/S from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of GMAB. Orbis Allan Gray Ltd increased its position in shares of Genmab A/S by 102.8% during the first quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company's stock worth $111,816,000 after purchasing an additional 2,895,179 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Genmab A/S by 152.3% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company's stock worth $71,367,000 after purchasing an additional 2,084,966 shares in the last quarter. Deep Track Capital LP purchased a new stake in shares of Genmab A/S during the fourth quarter worth approximately $41,740,000. Two Sigma Advisers LP increased its position in shares of Genmab A/S by 168.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock worth $34,509,000 after purchasing an additional 1,038,400 shares in the last quarter. Finally, Two Sigma Investments LP increased its position in shares of Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock worth $35,612,000 after purchasing an additional 938,455 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Stock Up 0.9%

Genmab A/S stock opened at $24.54 on Wednesday. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $27.94. The company has a market capitalization of $15.74 billion, a price-to-earnings ratio of 12.33, a price-to-earnings-growth ratio of 7.06 and a beta of 0.95. The stock has a 50-day moving average price of $22.01 and a 200 day moving average price of $21.16.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The firm had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. Research analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.